Hokuriku Pharmaceutical: Investor Relations Activity Record Sheet for October 16, 2024
Hokuriku Pharmaceutical: Announcement on the holding subsidiary Haichang Pharmaceutical passing the drug GMP compliance inspection
Hokuriku Pharmaceutical: Announcement on the conversion of convertible corporate bonds to shares in the third quarter of 2024
Hokuriku Pharmaceutical: Announcement on approval for marketing of sodium sulfate chemical raw materials
Hokuriku Pharmaceutical: Investor Relations Activity Record Form for September 20, 2024
Hokuriku Pharmaceutical: Investor Relations Activity Record Form for September 11, 2024
Hokuriku Pharmaceutical: Investor Relations Activity Record Form for September 9, 2024
Hokuriku Pharmaceutical: Investor Relations Activity Record Form for September 6, 2024
Hokuriku Pharmaceutical: Announcement of Resolutions of the 20th Meeting of the 8th Board of Directors
Hokuriku Pharmaceutical: Announcement on not revising the Hokuriku debt-for-share conversion price downward
Hokuriku Pharmaceutical: Investor Relations Activity Record Form for September 5, 2024
Hokuriku Pharmaceutical: Announcement on approval for marketing of the holding subsidiary Haichang Pharmaceutical\'s iodoxanol chemical raw material
Hokuriku Pharmaceutical: 2024 Semi-Annual Results Briefing Investor Relations Activity Record Form
Hokuriku Pharmaceutical: Investor Relations Activity Record Form for August 30, 2024
Hokuriku Pharmaceutical: An indicative announcement on the Hokuriku Convertible Bonds Expected to Trigger Conditions for a Downward Revision of the Exchange Price
Hokuriku Pharmaceutical: Investor Relations Activity Record Form for August 28, 2024
Hokuriku Pharmaceutical: Special Report on the Deposit and Use of Funds Raised for the Semi-Annual Year 2024
Hokuriku Pharmaceutical: Semi-Annual Report 2024
Hokuriku Pharmaceutical: Announcement of Supervisory Board Resolutions
Hokuriku Pharmaceutical: Announcement of Board Resolutions
No Data
No Data